The deal settles 80,000 US court cases related to allegations that Zantac was contaminated with a suspected carcinogen.

GSK settles 93% of Zantac lawsuits with a $2.2 billion payout, easing investor concerns. However, doubts over its future ...

GSK Plc said it will pay as much as $2.2 billion to resolve about 80,000 US court cases related to allegations that its old reflux medication Zantac was contaminated with a suspected carcinogen.

GSK has agreed to pay up to $2.2 billion to resolve approximately 80,000 lawsuits brought by users of Zantac who claimed the heartburn drug caused their cancer. The agreement frees the British ...

On Wednesday, GSK plc (NYSE:GSK) reached agreements with ten plaintiff firms representing approximately 80,000 Zantac product liability cases in the U.S. state courts. These cases account for 93% ...

GSK has agreed to pay up to $2.2 billion to settle most lawsuits in US state courts claiming that a discontinued version of the heartburn drug Zantac caused cancer, the company announced on ...

Another jury in the same courthouse handed a verdict last month to a separate Zantac manufacturer, GlaxoSmithKline. On May 23, an Illinois jury sided with both drug manufacturers in the first ...

The British pharmaceutical giant said Wednesday that it had struck agreements with 10 plaintiff firms aimed at resolving 93%, or about 80,000, of pending Zantac lawsuits in the country for up to ...

GSK has reached a $2.2bn settlement to resolve the vast majority of cases linked to its heartburn medicine Zantac, in a move that will help assuage legal concerns overhanging the UK drugmaker.